All In Biotech

Drug Trial Radar · NCT03823300

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (LUCERNE)

Last checked: Nov 20, 2026Latest source record: Jul 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 658 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

658

Actual

Start

Mar 11, 2019

Primary completion

Oct 5, 2020

Study completion Jan 7, 2022

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jan 30, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD).

Conditions

  • Wet Macular Degeneration

Interventions

  • FaricimabDrug

    Faricimab will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.

  • AfliberceptDrug

    Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks (Q8W).

  • Sham ProcedureProcedure

    The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatment arms at applicable visits to maintain masking.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48Time frame: From Baseline through Week 48

Locations

137 sites in 21 countries. Site status is shown where the registry gives one.

  • Associated Retina Consultants

    Phoenix, Arizona

  • Arizona Retina and Vitreous Consultants

    Phoenix, Arizona

  • Northern California Retina Vitreous Associates

    Mountain View, California

  • Retinal Consultants Med Group

    Sacramento, California

  • Orange County Retina Med Group

    Santa Ana, California

  • California Retina Consultants

    Santa Barbara, California

  • Colorado Retina Associates, PC

    Golden, Colorado

  • Retina Group of Florida

    Fort Lauderdale, Florida

  • Retina Care Specialists

    Palm Beach Gardens, Florida

  • Southern Vitreoretinal Assoc

    Tallahassee, Florida

  • Retina Associates of Florida, LLC

    Tampa, Florida

  • Southeast Retina Center

    Augusta, Georgia

  • Georgia Retina PC

    Marietta, Georgia

  • Retina Consultants of Hawaii

    ‘Aiea, Hawaii

  • University Retina and Macula Associates, PC

    Oak Forest, Illinois

  • Prairie Retina Center

    Springfield, Illinois

  • Raj K. Maturi, MD PC

    Indianapolis, Indiana

  • Wolfe Eye Clinic

    West Des Moines, Iowa

  • Maine Eye Center

    Portland, Maine

  • The Retina Care Center

    Baltimore, Maryland

  • Cumberland Valley Retina PC

    Hagerstown, Maryland

  • Retina Specialists

    Towson, Maryland

  • Ophthalmic Consultants of Boston

    Boston, Massachusetts

  • VitreoRetinal Surgery, PLLC.

    Minneapolis, Minnesota

  • Mid Atlantic Retina - Wills Eye Hospital

    Cherry Hill, New Jersey

  • Island Retina

    Shirley, New York

  • Retina Assoc of Cleveland Inc

    Cleveland, Ohio

  • The Ohio State University Havener Eye Institute

    Columbus, Ohio

  • Midwest Retina

    Dublin, Ohio

  • Palmetto Retina Center

    West Columbia, South Carolina

  • Southeastern Retina Associates Chattanooga

    Chattanooga, Tennessee

  • Retina Res Institute of Texas

    Abilene, Texas

  • Austin Retina Associates

    Austin, Texas

  • Austin Clinical Research LLC

    Austin, Texas

  • Retina Center of Texas

    Grapevine, Texas

  • Retina Consultants of Houston

    The Woodlands, Texas

  • Strategic Clinical Research Group, LLC

    Willow Park, Texas

  • Retina Associates of Utah, PLLC

    Murray, Utah

  • Piedmont Eye Center

    Lynchburg, Virginia

  • Wagner Kapoor Institute

    Norfolk, Virginia

Showing 40 of 137 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.